High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients-Reference-Cited by-同舟云学术

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients

Published:2016-06-15 Issue:8 Volume:91 Page:755-762
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Guolo Fabio¹,Minetto Paola¹,Clavio Marino¹,Miglino Maurizio¹,Di Grazia Carmen²,Ballerini Filippo¹,Pastori Giordana¹,Guardo Daniela¹,Colombo Nicoletta¹,Kunkl Annalisa³,Fugazza Giuseppina¹,Rebesco Barbara⁴,Sessarego Mario¹,Lemoli Roberto Massimo¹,Bacigalupo Andrea²,Gobbi Marco¹

Affiliation:

1. Hematology Clinic, Department of Internal Medicine (DiMI); University of Genoa, IRCCS AOU S. Martino-IST; Genoa Italy

2. Second Division of Hematology and Bone Marrow Transplantation; IRCCS AOU S. Martino-IST; Genoa Italy

3. Service of Flow-Cytometry, Department of Pathology; IRCCS AOU S. Martino-IST; Genoa Italy

4. Pharmacology Division; IRCCS AOU S. Martino-IST; Genoa Italy

Publisher

Wiley

Subject

Hematology

Reference46 articles.

1. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia;Burnett;J Clin Oncol,2012

2. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: A meta-analysis of individual patient data from randomized controlled trials;Hills;Lancet Oncol,2014